Abstract
We exploited the emerging potential of gene therapy strategies to design a powerful therapeutic system that combines two key components—AAV vector and [6]-gingerol. In this study, we created an AAV2 construct expressing the proapoptotic protein BIM, which uses HSPG as its primary receptor, to target HSPG-overexpressing melanoma cells. This combination treatment showed promising results in vitro, inducing apoptosis in human melanoma cells. This new platform technology will make a significant contribution to numerous therapeutic applications, most notably for melanoma, including overcoming resistance to conventional anticancer therapies.
Original language | English |
---|---|
Pages (from-to) | 194-199 |
Number of pages | 6 |
Journal | New Biotechnology |
Volume | 37 |
DOIs | |
Publication status | Published - 2017 Jul 25 |
Bibliographical note
Publisher Copyright:© 2017 Elsevier B.V.
All Science Journal Classification (ASJC) codes
- Biotechnology
- Bioengineering
- Molecular Biology